INTRODUCTION
Convulsive status epilepticus is a common emergency condition in paediatric practice. Classically, it is defi ned as continuous or recurrent seizure activity lasting for longer than 30 min in which the patient does not regain baseline mental status. 1 Commonly, intervention is recommended after only 5 min of seizure activity 2 as neuronal damage may begin to occur after this period, and the longer a seizure continues, the less likely it is to stop spontaneously. 3 It seems likely, however, that mortality and morbidity after prolonged seizures should often be dependent upon underlying aetiology rather than duration of seizure activity. 4 Repetitive serial seizures (ie, seizure clusters with return to baseline between events, but occurring frequently enough to be highly disruptive) and non-convulsive status epilepticus are also relatively common in children with epilepsy and are associated with signifi cant morbidity. 5 Diazepam, lorazepam and midazolam, the drugs most widely used to stop prolonged seizures, are members of the benzodiazepine family, a class of psychoactive drugs with varying hypnotic, sedative, anxiolytic, anticonvulsant, muscle relaxant and amnesic properties. 6 Differences in their affi nity for receptor subtypes account for different pharmacological effects, in combination with widely varying pharmacokinetic profi les. These pharmacokinetic differences often impose specifi c routes of administration and specifi c formulations for individual members of the benzodiazepine family. The aim of this review is to detail their clinical pharmacology as it relates to their use in the management of prolonged seizures in children.
HOW DO THEY WORK?
Benzodiazepines produce their range of effects by modulation of the γ-aminobutyric acid receptor subtype A (GABA A ). The GABA A receptor comprises fi ve subunits; each receptor is assembled from a combination of polypeptides, most commonly two αs, two βs and one γ, although several other subunits exist (eg, δ, ε, π, θ and ρ). 7 The combination of different subunits governs the pharmacological characteristics of each individual receptor and different subtypes have varying distributions within the central nervous system. 8 When GABA binds to the receptor, it opens its associated chloride ion channel, generating an inhibitory current, expressing the neurotransmitter's inhibitory effect.
Benzodiazepines bind to the γ subunit of the GABA A receptor at its interface with the α subunit. The allosteric binding of benzodiazepine to this site enhances the binding of GABA to the receptor and enhances the chloride channel's conductance by increasing the frequency of gated channel opening and hyperpolarising the membrane of the associated neuron. 9 The basic structure of benzodiazepines is formed from the fusion of a benzene ring and a diazepine ring. Benzodiazepine potency refers to the strength of the affi nity of the individual drug (or its active metabolites) for the GABA A receptor. 10 The relative structures and potency of lorazepam, diazepam and midazolam are summarised in fi gure 1.
Each member of the benzodiazepine family has different physicochemical properties, especially lipid solubility, which impact upon their absorption, distribution into tissue compartments, metabolism and excretion. These unique pharmacokinetic profi les have a major impact on the choice of a particular benzodiazepine for a particular condition, particularly in relation to route of administration, rate and extent of absorption. These are all key considerations when considering treatment of status epilepticus.
Some absorption and distribution pharmacokinetic parameters in adults of lorazepam, diazepam and midazolam are compared in table 1. Most benzodiazepines are rapidly and extensively absorbed when administered orally. The exception to this is midazolam, the only watersoluble benzodiazepine, which is metabolised by cytochrome P450 (CYP) enzyme 3A5 in the intestinal epithelium, 11 and thus has limited oral bioavailability. Benzodiazepines exert their pharmacological effect by crossing the blood-brain barrier, the rate of which is determined largely by their lipid solubility. Again, midazolam is an exception. Although it is water soluble at low pH (<4), this is due to opening of its diazepine ring between the 4 and 5 positions. At physiological pH this ring is closed accounting for an increase in its lipid solubility. 12 Pharmacokinetic metabolism and elimination parameters for lorazepam, diazepam and midazolam in adults are summarised in table 2. The elimination half-life of a benzodiazepine or its active metabolites is used to classify the duration of its effect. Thus lorazepam and midazolam with elimination half-lives of <10 h are termed short acting, whereas diazepam with an elimination half-life of >24 h is long acting. Benzodiazepine metabolism is mostly performed by CYP-dependent isoenzymes. distribution half-lives. Following this initial distribution, they are redistributed into less wellperfused tissues; a redistribution which is most rapid for those benzodiazepines with the greatest lipophilicity. 14 Route of administration clearly has a major impact on the speed of onset of anticonvulsant properties for benzodiazepines and this will be dealt with later. However, after intravenous administration of 10 mg diazepam and 4 mg of lorazepam, onset of action ranged from immediate to 10 min (median 2 min) for the former and immediate to 15 min (median 3 min) for the latter in a double-blind trial of both drugs in adult patients in status epilepticus. 15 In an uncontrolled report of the use of midazolam in 20 adult patients presenting to an emergency department with seizures (12 in status epilepticus), all seizure activity was stopped in less than 1 min. 16 It is clear therefore, that once these benzodiazepines are present within the intravascular space, their effect is rapid.
There is relatively sparse data available to attempt to quantify the minimum plasma concentrations at which each of the benzodiazepines is effective in suppressing seizure activity. For diazepam, a plasma concentration of between 200 and 600 μg/l is thought to be adequate. 17 18 For lorazepam, the fi gures are less certain, although a plasma concentration of 20-30 μg/l improved seizure control in patients with intractable partial seizures. 19 For midazolam, a therapeutic plasma concentration has not been defi ned. However, there appears signifi cant intraindividual variability of threshold plasma concentrations for each benzodiazepine, beyond which brain seizure activity will cease. There are several reasons for this. Animal studies indicate that neuronal surface expression of benzodiazepine-sensitive GABA A receptors is reduced by continuing electrical activity, 20 suggesting that the longer a seizure persists, the higher the plasma concentration of benzodiazepine required to stop it. Since most studies recruit a heterogeneous group of patients having seizures of varying durations, this introduces inherent variability when trying to defi ne a therapeutic plasma concentration. This heterogeneity of patient and cause for prolonged seizures contributes to variability in other ways: evidence is emerging that individual pathologies may increase benzodiazepine pharmacoresistance in seizures. 21 Other methodological shortcomings play their part: when considered, the establishment of minimal therapeutic concentrations is almost always a more minor objective of effi cacy trials and therefore robust studies are limited.
How long do they work for?
Length of anticonvulsant effect for the different benzodiazepines has been generally determined from non-comparative studies. In spite of its long elimination half-life, diazepam appears to have a short duration of anticonvulsant effect of about
Pharmacokinetics in children
There is more limited information related to the disposition of benzodiazepines in children; these studies are detailed in table 3. The ontogeny of the CYP-dependent metabolism pathways is likely to alter benzodiazepine clearance. CYP activity is low at birth, increasing to supranormal adult levels at age 2-3 years before gradually declining to adult levels by age 4. 13 In particular, these differences explain the much longer elimination half-life seen in preterm infants.
CLINICOPHARMACOKINETIC CORRELATES
Ideally, a drug used to treat prolonged seizures or status epilepticus should have a rapid onset of action and a prolonged effect, with an absence of unwanted side effects.
How quickly do they work?
The rapid entry of benzodiazepines to the central nervous system and other tissues with a good blood supply is commensurate with their short 24 This is related to its short elimination half-life combined with its lipid solubility causing rapid redistribution from the intravascular space, followed by rapid excretion, after its initial anticonvulsant effect.
Side effects
Although generally well tolerated, as a class, the benzodiazepines have a number of adverse effects. Drowsiness, confusion, amnesia and hangover effects are all commonly reported during routine use. However, the most relevant of these relating to the treatment of prolonged seizures is the risk of respiratory depression leading to a requirement for intubation and ventilatory support. In a North London cohort of children treated for convulsive status epilepticus, more than two doses of benzodiazepines were associated with respiratory depression (OR=2.9, 95% CI 1.4 to 6.1). 25 In practice, lorazepam has been reported to be associated with less respiratory depression than diazepam, with one prospective comparison in children reporting a rate of 4% for lorazepam compared with 21% for diazepam when given intravenously. 26 This is confi rmed by other retrospective case series. 27 28 
HOW SHOULD THE DRUG BE GIVEN? Intravenous route
It is clear that the intravenous route is the most re liable and rapid way to administer benzodiazepines in prolonged seizures. In the UK, guidelines for the management of prolonged seizures in children 29 suggest that of the benzodiazepines, lorazepam is the preferred initial intravenous drug, supported by data showing an equivalent effi cacy with diazepam, a longer duration of action and a lower reported incidence of respiratory depression. 26 30 However, its major drawback is the perceived need for intravenous access, the achievement of which can be diffi cult in small children, and is unlikely to be achieved out of hospital. The apparent need for rapid termination of prolonged seizures would mandate a treatment that could be administered by parents, caregivers or paramedics early in the course of presentation. This has led to the investigation of alternative routes of administration of benzodiazepines and a number of studies have examined plasma concentrations in children after administration via non-intravenous routes. These are summarised in table 4. The lack of a defi ned threshold therapeutic plasma concentration for each of the benzodiazepines means that although each of the drugs appear to be absorbed via these routes, comparative trial data are required to interpret their relative effi cacy.
The results of comparative trials in children are summarised in table 5. Six were considered in a Cochrane review of the management of tonic-clonic convulsions in children, 31 but only four of those listed were incorporated and the other two 32 33 were excluded because they included some patients over the age of 16 years 32 and included seizure types other than tonicclonic. 32 33 All the trials listed are of variable quality-it is beyond the remit of this review to consider this in detail; however, differences in the detail with which each study reported defi nitions of termination of seizure activity, seizure recurrence and adverse effects-for example, respiratory depression, complicate direct comparisons. In addition, comparing one drug given intravenously with another given by a transmucosal route is probably not fair and makes interpretation more fraught, particularly when trying to select the best drug for prehospital use. For this reason, the data for the studies have been grouped according to administration route. 
Rectal route
The rectal route is a well-tolerated route of administration which, in the case of diazepam, has been used widely. It can provide rapid and reliable absorption. However, variable effi cacy has been reported. Recent comparative studies demonstrate treatment success in 27-88.5% (table 5) . This may be a refl ection of differences in the aetiology of the seizures.
Lorazepam is also well tolerated when administered by the rectal route. Its rate of absorption appears to be slow with a t max of 67.5 ± 42.1 min in healthy adult volunteers. 34 Only one small trial has studied its effi cacy, demonstrating that of six children treated, all responded successfully. 26 Midazolam has been shown to be rapidly absorbed from the rectum in children. 35 36 However, no effi cacy data have been published.
Intranasal route
The intranasal route for delivery of benzodiazepines has been the focus of signifi cant interest in recent years, particularly with regard to group.bmj.com on November 4, 2016 -Published by http://ep.bmj.com/ Downloaded from midazolam. For diazepam, some pharmacokinetic data exist: after intranasal administration of diazepam to nine adult volunteers, a t max of 18 ± 11 min was observed with bioavailability of 50.4 ± 23.3%, 37 but no trial appears to have been carried out in clinical practice.
Intranasal lorazepam has recently been demonstrated to be an effective, safe, non-invasive treatment for prolonged seizures in children in Malawi, using a dose of 100 μg/kg in an open randomised trial compared with intramuscular paraldehyde. 38 A signifi cant number of clinical studies have been carried out in children relating to the effi cacy of intranasal midazolam for seizures (table 5) . Equivalent effi cacy has been reported in headto-head comparisons with intravenous diazepam 39 40 and it appears to be better than rectal diazepam. 31 33 
Buccal route
The buccal or sublingual route is growing in popularity for the delivery of benzodiazepines for acute seizures, with buccal midazolam replacing rectal diazepam as the preferred treatment in some centres when the intravenous route is not available. It is more socially acceptable than the rectal route and seems to be preferred to the intranasal route as it may provide less variable absorption. 41 An audit of the administration of the rectal formulation of diazepam into the buccal cavity in children suggests possible effi cacy, 42 but there is little other published evidence.
For midazolam, however, the route has been examined extensively. In children with malaria, a median t max of 10 min (range 5-40) has been reported with 87% bioavailability compared with intravenous administration 43 and there is good evidence of its clinical effi cacy. In head-to-head comparisons with rectal diazepam, buccal midazolam has demonstrated equivalent or superior effi cacy. 32 44 45 The pharmacokinetics of lorazepam following buccal administration have been characterised in healthy adult volunteers. After administration of a 2 mg sublingual tablet of lorazepam, median t max was 2.25 h with systemic availability of 98.2% compared with the intravenous route. 46 This study recognised that C max and t max could be improved by using a preparation of lorazepam that was more easily absorbed, since the in vitro dissolution rate of the tablet was reported as 84% in 1 h. There is little clinical experience, however, with the use of buccal lorazepam in seizures. Only one report, an uncontrolled case series, could be identifi ed. In that study, 10 children with intractable epilepsy and serial seizures were treated with sublingual tablets of lorazepam. 47 Eight children responded and had no subsequent seizures and two had a partial response. The lorazepam was felt to be effective 5-30 min after administration.
CONCLUSION
Acute tonic-clonic seizures, including convulsive status epilepticus are signifi cant problems in children and early treatment may shorten episodes and prevent subsequent mortality and long-term morbidity. In addition, non-convulsive status epilepticus and repetitive, serial seizures are relatively common phenomena in a number of the paediatric epilepsy syndromes as well as non-syndromic refractory epilepsy. These conditions are commonly treated with benzodiazepines, 48 49 though there is limited evidence, with patients having repetitive, serial seizures often included in studies of the management of prolonged seizures. 50 There is a need for an effective treatment for seizure termination that can be given by parents and carers in the community, and also within the hospital setting while intravenous access is achieved. For many years, diazepam administered rectally has fulfi lled this role, though more recently midazolam administered buccally has started to supersede it. In a number of studies in children, buccal midazolam has been proved to be as effective, if not more effective, than rectal diazepam, 32 44 45 and it is more acceptable to carers and children for the drug to be administered into the mouth, rather than rectally. 51 Studies of lorazepam demonstrate certain benefi cial features that may elevate it above other drugs in the benzodiazepine class as treatment for prolonged seizures, particularly in relation to its duration of action and its lower incidence of respiratory depression. Its limitations relate to apparent restrictions relating to its route of administration. As a result, further evaluation of the absorption of an appropriate formulation of lorazepam via the buccal route is warranted, in addition to further comparisons of the intranasal route with other transmucosal benzodiazepines in children. It is clear, however, that at present the perfect drug does not exist.
